
Loading, please wait...

Loading, please wait...

Uncontrolled type 2 diabetes remains a critical health challenge, particularly in underserved populations. Recent studies emphasize that a CGM access pharmacist intervention can significantly bridge the technology gap for these patients. Continuous glucose monitoring (CGM) provides real-time insights, yet financial and logistical hurdles often prevent its use. Consequently, the integration of clinical pharmacists into primary care settings has emerged as a successful strategy to enhance patient outcomes.
Pharmacists play a multifaceted role in managing diabetes technology. They assist patients through complex insurance navigation and provide essential hands-on education. Furthermore, pharmacists can interpret glucose data to make timely medication adjustments. Because of their accessible nature, pharmacists serve as a vital link between patients and advanced diabetes care. Additionally, this model has shown to increase the 'Time in Range' (TIR) for patients who previously struggled with traditional finger-stick monitoring. Therefore, pharmacist involvement is key to achieving health equity in diabetes management.
Implementing these services requires a collaborative approach within healthcare teams. Pharmacists can coordinate device distribution and offer troubleshooting support. This reduces the burden on physicians and ensures that technology is utilized effectively. As a result, patients feel more empowered and engaged in their own care. Scaling this model could provide a blueprint for addressing health disparities across diverse clinical settings.
Pharmacists facilitate access by navigating payor requirements, managing prior authorizations, and providing direct patient education on device mechanics.
These programs typically lead to improved HbA1c levels, increased time in range, and better medication adherence through personalized data interpretation.
Yes, pharmacist-led models are highly scalable and effective in resource-limited communities, helping to mitigate financial and logistical barriers to care.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.
References
Pashaeimofrad A et al. Evaluating the role of pharmacist intervention in improving continuous glucose monitor access for patients with uncontrolled diabetes at an FQHC. Am J Health Syst Pharm. 2026 May 28. doi: undefined. PMID: 42207568.
American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S126-S144.
Shrestha S et al. Pharmacist-led diabetes mellitus management: A systematic review and meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022;47(3):303-317.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study explores how pharmacist-led initiatives at health centers improve access to CGM technology for patients with uncontrolled type 2 diabetes....
4 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday